Last reviewed · How we verify
Placebo (for Ketoprofen)
A placebo contains no active pharmaceutical ingredients and produces no pharmacological effect, serving as an inert control in clinical trials.
The placebo for Ketoprofen, developed by Sanofi, is used in clinical trials to serve as a control for assessing the efficacy and safety of Ketoprofen. Since it is a placebo, it does not contain any active pharmaceutical ingredients and is designed to mimic the appearance of Ketoprofen. The primary purpose of using a placebo is to differentiate the actual therapeutic effects of Ketoprofen from the psychological effects of receiving treatment. As a placebo, it has no pharmacological activity and is not associated with any specific side effects or drug interactions. However, patients may still report perceived side effects due to the placebo effect.
At a glance
| Generic name | Placebo (for Ketoprofen) |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inactive substances formulated to match the appearance of an active drug but contain no therapeutic agents. They are used in randomized controlled trials to establish the true efficacy of the active drug by comparison against a non-therapeutic control. Any observed clinical benefit from a placebo is attributable to the placebo effect—psychological and physiological responses to the expectation of treatment rather than direct drug action.
Approved indications
- Clinical trial control for Ketoprofen efficacy studies
Common side effects
Key clinical trials
- Multiprofen-CC to Reduce Pain in Hand Arthritis (PHASE3)
- Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty (PHASE3)
- Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room (PHASE3)
- Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery (PHASE3)
- Non-steroidal Anti-inflammatory Drugs in Pleurodesis (PHASE2)
- A Study to Assess Efficacy and Tolerability of Ketoprofen 40 mg Granules vs Placebo (PHASE3)
- Nonopioid Analgesics and Cholecystectomy (PHASE3)
- Lymphedema Study for Arm or Leg Lymphedema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Ketoprofen) CI brief — competitive landscape report
- Placebo (for Ketoprofen) updates RSS · CI watch RSS
- Sanofi portfolio CI